Rational Design and Characterization of 5‐Fluorouracil–Loaded Lipid–Polymer Hybrid Nanoparticles for Enhanced Transdermal Delivery in Skin Cancer Therapy
Drug Development Research · 2026-04 · 87 (2)
DOI: 10.1002/ddr.70254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 01.03.2026. Verfasst von Tenzin Sonam Dongsar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. Hauptthemen laut MEDLINE: Fluorouracil, Nanoparticles, Polymers, Lipids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 104 Literaturangaben. Gefördert von: Prince sattam bin Abdulaziz University.
Abstract (Originalsprache)
Effective management of skin cancer remains challenging due to limited transdermal drug penetration, systemic toxicity, and therapeutic resistance. In this study, 5‐fluorouracil (5‐FU)‐loaded lipid‐polymer hybrid nanoparticles (LPHNPs) were rationally engineered as a next‐generation nanocarrier system to overcome these barriers. The hybrid design synergistically combines the structural integrity of polymers with the biocompatibility and permeability‐enhancing attributes of lipids. Using a central composite design, formulation parameters were optimized to achieve favorable physicochemical characteristics, yielding nanoparticles with a mean diameter of 256.7 nm, a polydispersity index (PDI) of 0.2711, and a positive zeta potential of +25.47 mV, indicative of excellent colloidal stability. In vitro release and ex vivo permeation studies revealed a sustained drug release profile and significantly improved dermal penetration compared to conventional formulations. Moreover, the Hen's egg test‐chorioallantoic membrane (HET‐CAM) irritation assay confirmed the biocompatibility and reduced irritation potential of the developed system. Overall, the optimized 5‐FU‐loaded LPHNPs present a promising platform for localized, controlled transdermal chemotherapy, potentially minimizing systemic exposure and improving therapeutic efficacy in skin cancer management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
- Department of Pharmacology, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
- Department of Medical Laboratory, College of Applied medical sciences, Prince Sattam bin Abdulaziz University, Alkharj, Saudi Arabia.
- Faculty of Business and Communication, INTI International University, Nilai, Malaysia.
- Next-Generation Translational Nanomedicine Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh, India.
- Department of Research and Development, Asia University, Taichung, Taiwan.
ORCID-Profile: Khang Wen Goh, Prashant Kesharwani
Förderung
- Prince sattam bin Abdulaziz University
Zitieren
APA
Dongsar, T. S., Alqahtani, T., Shmrany, H. A., Goh, K. W., Ahmad, F. J., & Kesharwani, P. (2026). Rational Design and Characterization of 5‐Fluorouracil–Loaded Lipid–Polymer Hybrid Nanoparticles for Enhanced Transdermal Delivery in Skin Cancer Therapy. Drug Development Research, 87(2). https://doi.org/10.1002/ddr.70254
Vancouver
Dongsar TS, Alqahtani T, Shmrany HA, Goh KW, Ahmad FJ, Kesharwani P. Rational Design and Characterization of 5‐Fluorouracil–Loaded Lipid–Polymer Hybrid Nanoparticles for Enhanced Transdermal Delivery in Skin Cancer Therapy. Drug Development Research. 2026;87(2). doi:10.1002/ddr.70254
BibTeX
@article{Dongsar2026,
author = {Dongsar, Tenzin Sonam and Alqahtani, Taha and Shmrany, Humood Al and Goh, Khang Wen and Ahmad, Farhan Jalees and Kesharwani, Prashant},
title = {Rational Design and Characterization of 5‐Fluorouracil–Loaded Lipid–Polymer Hybrid Nanoparticles for Enhanced Transdermal Delivery in Skin Cancer Therapy},
journal = {Drug Development Research},
year = {2026},
volume = {87},
number = {2},
doi = {10.1002/ddr.70254}
}
EUVIMED